Trials / Completed
CompletedNCT00790192
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 488 (actual)
- Sponsor
- Sumitomo Pharma America, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe as compared with quetiapine XR short term among acutely psychotic patients with chronic schizophrenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lurasidone | Lurasidone 80 mg tablets |
| DRUG | Lurasidone | Lurasidone 4 40 mg tablets |
| DRUG | Quetiapine XR | Quetiapine XR 600mg |
| DRUG | Placebo | Matching Placebo to Lurasidone or Quetiapine |
Timeline
- Start date
- 2008-10-01
- Primary completion
- 2010-07-01
- Completion
- 2010-07-01
- First posted
- 2008-11-13
- Last updated
- 2016-03-17
- Results posted
- 2011-10-06
Locations
65 sites across 5 countries: United States, India, Romania, Russia, Ukraine
Source: ClinicalTrials.gov record NCT00790192. Inclusion in this directory is not an endorsement.